Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CPRX price target $9.00, up 3x from current pps.
TIPranks Andrew Fein, H.C. Wainwright is 1,641 of 5,169 Wall St Analysts : Click here.
* * $CPRX Video Chart 05-13-2019 * *
Link to Video - click here to watch the technical chart video
News: $CPRX Catalyst Pharmaceuticals Announces First Quarter 2019 Financial Results and Provides Corporate Update
-Firdapse® Launch Off to Strong Start with First Quarter Net Revenues of $12.4 Million -81 Patients Without Previous Access to any Form of Amifampridine Have Been Prescribed Firdapse -Company to Host Quarterly Conference Call at 8:30 am ET Today CORAL GABLES, Fla., May 13,...
Find out more https://marketwirenews.com/news-releases/catalyst-pharmaceuticals-announces-first-quarter-2019-financial-results-and-provides-corporate-update-8171822.html
* * $CPRX Video Chart 05-10-2019 * *
Link to Video - click here to watch the technical chart video
* * $CPRX Video Chart 05-09-2019 * *
Link to Video - click here to watch the technical chart video
Can't believe it. Just bought another load at $2.36 It's totally a gift. Thank you. Anyone want to sell at $2 ? Just let me know.
Ridiculously oversold. I started buying at 2.72 and will continue to buy if it drops more. Sorry for the bagholders, but it's easy money now at these levels.
Why is the price tanking after this contract award today?
https://www.fbo.gov/?s=opportunity&mode=form&id=a21b849ce3c5d9eb4e2875cbce4f2094&tab=core&_cview=1
Read this. Once the dust settles CPRX will go back up and higher.
https://tomwelch12345.wordpress.com/category/fda-violations/
* * $CPRX Video Chart 05-07-2019 * *
Link to Video - click here to watch the technical chart video
By the way, Jacobson Pharma owner has no interest in marketing their drug to adults 👇🏼 pic.twitter.com/0rBT23b1l1
— Kevin Wolcott (@Kevin_W81) May 7, 2019
Have held this stock for so many years I have forgotten most of the issues extant between Cat and Jac. Now, doctors might prescribe the Jac composition, off-label, for adult use. Then:
1) How similar is the Jac composition to the Cat composition? Identical? Similar enough to be equivalent in function and use? I assume Cat has one or more patents embracing its own composition and method for treating LEMS in at least adults.
2) Does Jac have patents encompassing its composition? If Jac does have such patent(s), did Jac file its patent application(s) earlier than Cat filed its patent application(s)? The first party to file a patent application after March 16, 2013 that ensues to a patent grant has priority over a second party under AIA.
3) Did either Jac or Cat file its patent applications prior to March 16, 2013? The AIA statutory law retains the principle that the patent right is granted to the first inventor if that inventor filed its application with an effective filing date before March 16, 2013. The party that asserts first inventorship would have the burden of establishing that fact.
4) The above questions embrace some broadly stated concepts that may become relevant to what happens next. Time to start some homework to refresh memory. I have ignored any NCE status the respective compositions might possess under the Food and Drug laws and regulations
5) Like many others, we have accumulated many tens of thousands of shares; ours have a composite basis of less than $1.00/share.
The reasoning in the article makes zero sense. There are hardly any pediatric patients. The market is 99% adults. This is fake news and they have been manipulating CPRX since last December when they tanked the PPS below two after FDA approval. Buy more tomorrow below $4 because it's a steal. This is a bear raid.
I just invested this week. What is happening after hours???
Wow...this stock is getting smoked afterhours...down 50%
Time to buy more i think
That approval wont have any effect on the adult population
Next week earnings release will be interesting. 8th!
* * $CPRX Video Chart 04-25-2019 * *
Link to Video - click here to watch the technical chart video
Turn off the volume and we wait for earnings or News on MuSK study. We wake up to $8-$10 per share.
$CPRX. Lookin good ! Ready for April 2019. $10-$12
* * $CPRX Video Chart 03-27-2019 * *
Link to Video - click here to watch the technical chart video
I see $ 5.59, another high
never mind mine are EMA yours are SMA that would make sense. EMA seems to be a better indicator for GC setups.
that already happened 3/21 hence the move...
* * $CPRX Video Chart 03-26-2019 * *
Link to Video - click here to watch the technical chart video
* * $CPRX Video Chart 03-25-2019 * *
Link to Video - click here to watch the technical chart video
* * $CPRX Video Chart 03-21-2019 * *
Link to Video - click here to watch the technical chart video
* * $CPRX Video Chart 03-20-2019 * *
Link to Video - click here to watch the technical chart video
* * $CPRX Video Chart 03-19-2019 * *
Link to Video - click here to watch the technical chart video
we may add: Insurance Coverage for all ODD payments must be ensured. This addresses the released individual suffering from being rejected insurance and fears a $100k co-pay.
If it is in the society's interest (and it should be) that no patient is left behind, the community has to make a choice.
Either:
(1) Develop ODD Therapies all publicly funded and market it by the state - or -
(2) Let private companies take the financial risk upfront and reimburse them later on via high drug prices (status quo)
You see that (1) will probably incur higher costs, as the public will need to also finance all the failures.
FDA may also preempt certain ODD development like in this case, if they believe current unproven alternatives are more in the public interest. However, this was not the case here, FDA has chosen the current path.
Bottom line: No patient shall be left behind and they all shall sit at one table and clarify complete payment.
It is surely outrageous that the insurance company does not pay 100%.
Just my 2c
Bernie Sanders bashes $CPRX for ODD Economics again
It is funny to watch CPRX being bashed by this Bernie Sanders for the ODD pricing model. A Senator yelling around trying to kill the economics of rare disease drug development.
Nasty and harming all potential patients.
CPRX's reply earlier was https://ir.catalystpharma.com/static-files/9d93296c-de07-4691-9aa6-2ed9478bffc0
Jacobus only addressed 200 of the 3000 patients and their unstable drug variation has a short shelf life and must be cooled at all times. CPRX's variation can be stored at room temperature.
This was Sanders's second weirdo approach.
Company released a news item to support Rare Disease Day 2019, surely for awareness. https://finance.yahoo.com/news/catalyst-pharmaceuticals-announces-support-rare-130300799.html
ODD drug development costs money & time, regardless weather you purchase the molecule/compound or 'find' it yourself. Subsequent clinical trials consume quite some money to please exactly what the FDA requires: Compliance.
Removing ODD regulations would open a wormhole of lawsuits and threaten the economics of rare disease drug development.
It would threaten the very people benefiting from these rules: The patients. No pharma would be able to develop these drugs otherwise.
(Compilation of thoughts from SoS and myself)
#cprx Boom!!!!On it’s way to 52 week high!!
Oh wouldn’t complain...
ABSOLUTELY fellt the BERN thnx bernie for the free advertisement.
$cprx this goes to $6-$8 with Bernie’s help paying attention to LEMS
If we longs are lucky we will see more naked short activity in the weeks ahead only to help boost stock price further higher
Bernie will give CPRX more press on more indications for use! It’s a win-win!
Sold for 10% gain. Will buy again in a week or so.
Sold for small gains at $2.40
Will watch for bottom.
Looks promising in 2019/2020
Interesting CPRX trading data from Friday. Slapping the Ask really heated up late day & throughout the after hours session. Traded on Ask 1.6M shares(51%), traded on Bid 1.1M shares(35%) & traded in between 462K shares(14%).
As for short selling, the last bi-weekly report on 11/30/18 showed a 32% increase in short interest. However, the daily short sale info on Fintel, FINRA & NakedShortReport have all seen daily shorting declines the past 2 days. IMHO today's low of 1.85 was probably the bottom of this irrational CPRX pullback. GLTL
Holding this down / then 2019 we see what’s up!!!
Bounced off low of 2.18 nicely. CC on 12/13
Could go either way depending on The CC
Small bounce this morning. If we hold green today and repeat on Monday we may see $3+ again soon
Followers
|
183
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
4126
|
Created
|
04/23/07
|
Type
|
Free
|
Moderators |
Q2-19 Financial Results
Recent Developments and Highlights
Upcoming Milestones
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |